<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2148">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04350086</url>
  </required_header>
  <id_info>
    <org_study_id>87RI20_0011 (PRODEX)</org_study_id>
    <nct_id>NCT04350086</nct_id>
  </id_info>
  <brief_title>Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection</brief_title>
  <acronym>PRODEX</acronym>
  <official_title>Prospective Study of the Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current sars-cov-2 epidemic is responsible for severe respiratory infections leading to
      end-of-life situations.

      Dexmedetomidine may be indicated in mild to moderate sedation in palliative patients, due to
      its pharmacological characteristics.

      The hypothesis of this study is that Dexmedetomidine would allow effective and safe light
      sedation in patients with respiratory failure in palliative situations suffering from
      Covid-19 infection.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    unfavorable opinion of the ethics committee
  </why_stopped>
  <start_date type="Anticipated">April 20, 2020</start_date>
  <completion_date type="Anticipated">November 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of mild to moderate palliative sedation induced by Dexmedetomidine.</measure>
    <time_frame>Day 30</time_frame>
    <description>Number of days of mild to moderate sedation induced by dexmedetomidine until death or change of molecule.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival of patients on Dexmedetomidine</measure>
    <time_frame>Day 30</time_frame>
    <description>Overall survival time in days from inclusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily analgesic effect of Dexmedetomidine</measure>
    <time_frame>Day 30</time_frame>
    <description>The daily effectiveness of Dexmedetomidine on pain assessed by the NCS-R scale (Nociception Coma Scale) : the score is between 0 and 9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other sedative pharmacological agents</measure>
    <time_frame>Day 30</time_frame>
    <description>Number of the various sedative molecules used in the subjects of the study in addition to Dexmedetomidine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average dosage required for Dexmedetomidine to achieve mild to moderate sedation</measure>
    <time_frame>Day 30</time_frame>
    <description>Daily dosage measurement in ug / kg / h of Dexmedetomidine necessary to obtain light to moderate sedation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>COVID-19 Infection</condition>
  <condition>Sars-cov-2</condition>
  <condition>Respiratory Failure</condition>
  <condition>Palliative Situation</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment with Dexmedetomidine</intervention_name>
    <description>Administration of Dexmedetomidine in continuous infusion by electric syringe pump at a dose of 0.4 Âµg / kg / h, with dose adjustment according to the sedation score and tolerance.</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Major patient

          2. Relating to palliative care

          3. With sars-cov-2 infection

          4. Requiring light to moderate sedation corresponding to a RASS score of -1 to -3

        Exclusion Criteria:

          1. Pregnant, lactating woman.

          2. Hypersensitivity to the active substance or to any of the excipients listed in section
             6.1 of the summary of product characteristics

          3. Advanced heart block (level 2 or 3) unless a pacemaker.

          4. Uncontrolled hypotension.

          5. Acute cerebrovascular pathologies.

          6. Use of other sedative drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Limoges</city>
        <zip>87200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 13, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>sars-cov-2</keyword>
  <keyword>infection</keyword>
  <keyword>respiratory failure</keyword>
  <keyword>palliative situation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

